

my NEWS

AUGUST 2026



A MESSAGE FROM OUR PRESIDENT & CEO

Dear CCRAN Community,

August has been a month of momentum. Behind every advocacy campaign, every conversation with a patient, and every event we bring to our community, there is a simple goal: ensuring people affected by cancer are never left to navigate it alone.

At the top of this issue: **NEXERA-303**, a new Phase 3 clinical trial, is now enrolling patients with metastatic, microsatellite-stable (MSS) colorectal cancer (CRC) who have not yet begun treatment for their metastatic disease. Because eligibility depends on referral before first-line treatment begins, timing is critical.

We're also calling on patients with **ROS1-positive non-small cell lung cancer** to share their experiences with taletrectinib, and we're standing alongside Ovarian Cancer Canada to demand access to **ELAHERE** for those who need it. We're growing our team, too — if you know a creative storyteller looking for meaningful work, we're hiring a **Communications Coordinator**.

Beyond that, the **recordings from our 4th Annual Pan-Tumour Biomarkers Conference** are now available to anyone who couldn't join us virtually or live. Our **Jumbo Colon exhibit** is also ready to book for your next community event, health fair, or awareness day.

As always, thank you for staying engaged in this work. Every share, every phone call, and every conversation moves us closer to equitable care for all Canadians affected by cancer.

With gratitude,

F. Servidio-Italiano

Filomena Servidio-Italiano

President & CEO, CCRAN

IN THIS ISSUE

- **NEXERA-303: Now Enrolling Metastatic Patients Before Starting First-Line Treatment**

A new Phase 3 trial is enrolling people with metastatic, MSS CRC who have not yet started treatment for metastatic disease.

- **Have You Been Diagnosed With Non-Small Cell Lung Cancer (NSCLC)?**

Share your experience to help inform funding decisions about access to talrectinib in Canada.

- **Demand Access to ELAHERE for Ovarian Cancer Patients**

Add your voice to the call for publicly funded access to ELAHERE for eligible patients in Canada.

- **We're Hiring: Communications Coordinator**

Join CCRAN's mission-driven team and help amplify patient voices and advance equitable cancer care.

- **2026 Biomarkers Conference Recordings Are Live**

Catch up on expert-led sessions exploring equitable access to comprehensive genomic profiling (CGP) across Canada.

- **Book the Jumbo Colon for Your Next Event**

Book CCRAN's interactive Jumbo Colon to your next community event, health fair, or conference.

- **Toronto Declares Early Age Onset Cancer Awareness Day**

A Canadian first: Toronto recognizes November 19 as Early Age Onset Cancer Awareness Day.

- **CCRAN's 6th Annual Early Age Onset Cancer Symposium**

Save the date for November 19–20 and join the conversation on redefining care for younger adults with cancer.

NEW CLINICAL TRIAL OPPORTUNITY

NEXERA-303: Now Enrolling Metastatic Patients Before Starting First-Line Treatment

**ENROLL IN THE
NEXERA-303
CLINICAL TRIAL**

A new Phase 3 trial is enrolling people with **metastatic, microsatellite-stable (MSS) colorectal cancer** who have **not yet started treatment** for metastatic disease. Because eligibility requires referral before first-line treatment begins, timing is critical.



NEW CLINICAL TRIAL OPPORTUNITY

NEXERA-303: Now Enrolling Metastatic Patients Before Starting First-Line Treatment (continued)

Eligibility: Metastatic, unresectable MSS colorectal cancer; no prior treatment for metastatic disease; confirmed MSS biomarker status. Not for patients with dMMR/MSI-H or BRAF tumour mutations — unsure of your status? Contact your oncologist.

Recruiting now: Princess Margaret Cancer Centre (Toronto, ON)

Opening soon: Hôtel-Dieu de Lévis (Lévis, QC)
• CISSS de la Montérégie-Centre (Greenfield Park, QC) • Juravinski Cancer Clinic (Hamilton, ON) • Sunnybrook Research Institute (Toronto, ON) • Saskatoon Cancer Centre (Saskatoon, SK) • Cross Cancer Institute (Edmonton, AB)

For more information, contact: **Himanshi Singhvi**, National Patient Support Program Manager, CCRAN, himanshi.s@ccran.org
1-833-79-CCRAN (22726) ext. 1007

[Learn more](#)

PATIENT VOICES NEEDED


Have You Been Diagnosed With Non-Small Cell Lung Cancer (NSCLC)?

Taletrectinib is under funding review in Canada for locally advanced or metastatic ROS1-positive NSCLC. Patient organizations are gathering input from patients and caregivers to help decision-makers understand the real-world impact of this diagnosis and its treatments.

You can share your experience in two ways: **complete a short, confidential online survey** (open to anyone with advanced or metastatic NSCLC), or — **if you've specifically taken taletrectinib for ROS1-positive NSCLC** — take part in a confidential 45-minute phone interview with **Winky Yau** (winky@lungcancercanada.ca, 1-888-445-4403 ext. 5208).

Your voice can help get this therapy funded in Canada.

[Complete the survey](#)



Demand Access to ELAHERE for Ovarian Cancer Patients

ELAHERE (mirvetuximab soravtansine) is the first major new treatment option in more than 10 years for patients with FRa-positive, platinum-resistant ovarian cancer. Yet, despite its availability in other countries, eligible patients in Canada still can't access it through the public healthcare system.

CCRAN stands proudly with **Ovarian Cancer Canada** to demand access to this treatment for Canadians living with ovarian cancer.

Use their **online tool** to ask your provincial or territorial representative to help remove barriers that prevent women from accessing innovative treatments.



[Add your voice](#)

JOIN OUR TEAM!

We're Hiring: Communications Coordinator



CCRAN is seeking a creative storyteller fluent in English and French to amplify the voices of cancer patients, grow our national community, and support our communications strategy to advance equitable cancer care across Canada.

We're looking for someone with experience in: social media & digital communications • graphic design & short-form video • content writing & email marketing.

This fully remote role offers comprehensive benefits and a collaborative, purpose-driven team. Applications are reviewed as they're received, so don't wait to apply.

[View the job posting](#)

NOW AVAILABLE!

2026 Biomarkers Conference Recordings Are Live

Recordings from **CCRAN's 4th Annual Pan-Tumour Biomarkers Conference** are now available on demand!

This year's Conference brought together patients, clinicians, researchers, and policy leaders to advance discussions on equitable access to comprehensive genomic profiling (CGP) across Canada.

If you couldn't join us virtually or live, you can now revisit every session at your convenience.

[Watch the recordings](#)

COMMUNITY OUTREACH

Book the Jumbo Colon for Your Next Event




CCRAN's **Jumbo Colon** is an immersive, inflatable walk-through exhibit that's hard to miss!

Guided by audiovisual screens, visitors can see and feel the colon's various pathologies as they stroll through — including giant polyps, ulcerative colitis, Crohn's disease, diverticulitis, hemorrhoids, and the different stages of colon cancer. It's an engaging way to draw the public in and spark real conversations about colorectal cancer screening and prevention.

Available to book for your next community event, health fair, or conference.

Contact: **Don Wood**, Community & Patient Engagement Specialist, CCRAN, don.w@ccran.org, 1-833-79-CCRAN (22726) ext. 1003

[Learn more](#)



MARK YOUR CALENDAR • NOVEMBER 19

Toronto Declares Early Age Onset Cancer Awareness Day

NOV
19

EAOC Awareness Day
City of Toronto • A Canadian first

Toronto is now the **first city in Canada** to recognize **November 19** as Early Age Onset Cancer Awareness Day — a motion CCRAN was proud to bring forward.

Our goal: to see it marked across the country.

[Read the announcement](#)

SAVE THE DATE • NOVEMBER 19-20

CCRAN's 6th Annual Early Age Onset Cancer Symposium

NOV
19-20

Early Age Onset Cancer Symposium
2026 • Details coming soon

Mark your calendars for **November 19-20, 2026**. Our sixth annual Early Age Onset Cancer Symposium once again brings our community together from across Canada and beyond.

Stay tuned for agenda, speaker, and registration updates.

[Learn more](#)



CCRAN is a patient-focused organization dedicated to improving the longevity and quality of life for people affected by colorectal cancer across Canada. Stay connected with us for trusted education, resources, and updates from the colorectal cancer community.

[Make a Donation to CCRAN](#)